The global pharma giant cut more than 400 jobs in the state last year, after investing at least $360 million in its local manufacturing operations.

Regenxbio filed a lawsuit in 2020 alleging that Elevidys infringed a gene-therapy patent that the company licenses from ...

Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. | Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This ...

Biotech company Regenxbio and the University of Pennsylvania on Friday convinced a U.S. appeals court to revive their patent lawsuit against Sarepta Therapeutics over Sarepta's Duchenne muscular ...

Japan’s Chugai today announced that it launched Elevidys intravenous infusion (delandistrogene moxeparvovec), which received ...

Lasting gains in swallowing ability have been reported for four people with oculopharyngeal muscular dystrophy given gene therapy in a trial.

We expect investors to focus on pipeline updates when Keros Therapeutics KROS reports fourth-quarter results shortly. The Zacks Consensus Estimate for sales and loss per share is pegged at $6.50 ...

Guggenheim Securities Emerging Outlook: Biotech Summit 2026 February 12, 2026 10:30 AM ESTCompany ParticipantsAlexander ...

An advisory panel to Japan's health minister decided Friday to allow public health insurance coverage for a gene therapy for muscular dystrophy beginning Feb. 20 and set the drug's official price at ...

In a statement, PTC's chief executive, Matthew Klein, said the company had decided to pull the filing for Translarna (ataluren) as a treatment for nonsense mutation DMD after the FDA said it was ...

The FDA’s refusal to review Moderna’s mRNA-based flu vaccine is part of a larger communications crisis unfolding at the agency over the past nine months that has also ensnarled Sarepta, Capricor, ...

Among the 22 companies under coverage, the analysts highlight six stocks - Ionis, Beam, Taysha, Sarepta, Spyre, and RAPT, as their strongest ideas for 2026, reflecting robust pipelines, near-term data ...